Testing and Treatment for Osteoporosis Following Hip Fracture in an Integrated U.S. Healthcare Delivery System

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2011 Jan 29

PMID 21271339

Citations 26

Authors

A Shibli-Rahhal

M S Vaughan-Sarrazin

K Richardson

P Cram

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Older veterans with acute hip fracture do not receive adequate evaluation and treatment for osteoporosis, irrespective of their age and underlying health status.

Introduction: Hip fractures are a serious complication of osteoporosis, leading to high mortality and morbidity. Prior studies have found significant undertreatment of osteoporosis in women with hip fracture. We examined the rate of bone density (BMD) testing and osteoporosis treatment among a predominantly male population hospitalized with hip fractures.

Methods: We conducted a retrospective cohort study of patients age 65 years and older hospitalized in U.S. Department of Veterans Affairs (VA) hospitals with hip fracture (N = 3,347) between 1 October, 2004 and 30 September, 2006. The primary outcome was receipt of BMD testing or initiation of pharmacotherapy within 12 months of fracture.

Results: The mean age of the study population was 79.0 years (SD = 6.7), 96.5% were male, and 83.3% were white. Only 1.2% of hip fracture patients underwent BMD testing and 14.5% received osteoporosis therapy within 12 months of fracture. Among fracture patients with minimal comorbid illness (N = 756) only 1.6% underwent BMD testing and 13.0% received pharmacotherapy. In logistic regression models, treatment rates were higher for women compared to men (odds ratio, 3.30; 95% CI, 2.16-5.04) and lower for blacks compared to whites (odds ratio, 0.67; 95% CI, 0.45-0.99).

Conclusions: Evaluation and treatment of osteoporosis among patients with fractures is suboptimal even in an integrated healthcare delivery system with generous pharmaceutical coverage. This study suggests that the undertreatment of osteoporosis demonstrated in the private sector is also present within the VA.

Citing Articles

Integrated model of secondary fracture prevention in primary care (INTERCEPT): protocol for a cluster randomised controlled multicentre trial.

Wang M, Knight A, Demeshko A, Girgis C, Bolton P, Das A BMC Prim Care. 2024; 25(1):349.

PMID: 39342106 PMC: 11438153. DOI: 10.1186/s12875-024-02601-3.

Secondary fracture prevention in primary care: a narrative review.

Wang M, Seibel M Osteoporos Int. 2024; 35(8):1359-1376.

PMID: 38652313 PMC: 11281980. DOI: 10.1007/s00198-024-07036-1.

Age-dependent gender differences in the diagnosis and treatment of osteoporosis during hospitalization in patients with fragility fractures.

Li Q, Yang J, Tang Q, Feng Y, Pan M, Che M BMC Geriatr. 2023; 23(1):728.

PMID: 37946131 PMC: 10636910. DOI: 10.1186/s12877-023-04430-y.

Approach to the Patient With Bone Fracture: Making the First Fracture the Last.

Wang M, Seibel M J Clin Endocrinol Metab. 2023; 108(12):3345-3352.

PMID: 37290052 PMC: 10655538. DOI: 10.1210/clinem/dgad345.

Anti-osteoporotic Drug Utilization Rates for Secondary Prevention Among Patients with Osteoporotic Fractures.

Aypak C, Bircan M, Ozdemir A Rambam Maimonides Med J. 2022; 13(3).

PMID: 35701156 PMC: 9345764. DOI: 10.5041/RMMJ.10473.

References

Torgerson D, Dolan P . Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis. 1998; 57(6):378-9. PMC: 1752619. DOI: 10.1136/ard.57.6.378. View

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J . Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343(9):604-10. DOI: 10.1056/NEJM200008313430902. View

Bergstrom U, Bjornstig U, Stenlund H, Jonsson H, Svensson O . Fracture mechanisms and fracture pattern in men and women aged 50 years and older: a study of a 12-year population-based injury register, Umeå, Sweden. Osteoporos Int. 2008; 19(9):1267-73. DOI: 10.1007/s00198-007-0549-z. View

Al Attia H, Adams B . Osteoporosis in men: are we referring enough for DXA and how?. Clin Rheumatol. 2006; 26(7):1123-6. DOI: 10.1007/s10067-006-0406-z. View

Elliot-Gibson V, Bogoch E, Jamal S, Beaton D . Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. 2004; 15(10):767-78. DOI: 10.1007/s00198-004-1675-5. View

Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C . Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009; 20(10):1633-50. DOI: 10.1007/s00198-009-0920-3. View

Koval K, Zuckerman J . Functional recovery after fracture of the hip. J Bone Joint Surg Am. 1994; 76(5):751-8. DOI: 10.2106/00004623-199405000-00018. View

Riley R, Carnes M, Gudmundsson A, Elliott M . Outcomes and secondary prevention strategies for male hip fractures. Ann Pharmacother. 2002; 36(1):17-23. DOI: 10.1345/aph.1A094. View

Beringer T, Clarke J, Elliott J, Marsh D, Heyburn G, Steele I . Outcome following proximal femoral fracture in Northern Ireland. Ulster Med J. 2006; 75(3):200-6. PMC: 1891773. View

10.

Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, Mautalen C . Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357(18):1799-809. PMC: 2324066. DOI: 10.1056/NEJMoa074941. View

11.

Johnell O, Kanis J, Oden A, Sernbo I, Redlund-Johnell I, Petterson C . Fracture risk following an osteoporotic fracture. Osteoporos Int. 2003; 15(3):175-9. DOI: 10.1007/s00198-003-1514-0. View

12.

Roerholt C, Eiken P, Abrahamsen B . Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int. 2008; 20(2):299-307. DOI: 10.1007/s00198-008-0651-x. View

13.

Kaufman J, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky G . Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2004; 16(5):510-6. DOI: 10.1007/s00198-004-1713-3. View

14.

Johnell O, Kanis J . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-33. DOI: 10.1007/s00198-006-0172-4. View

15.

Kaufman J, Bolander M, Bunta A, Edwards B, Fitzpatrick L, Simonelli C . Barriers and solutions to osteoporosis care in patients with a hip fracture. J Bone Joint Surg Am. 2003; 85(9):1837-43. DOI: 10.2106/00004623-200309000-00030. View

16.

Klotzbuecher C, Ross P, Landsman P, Abbott 3rd T, Berger M . Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000; 15(4):721-39. DOI: 10.1359/jbmr.2000.15.4.721. View

17.

Kiebzak G, Beinart G, Perser K, Ambrose C, Siff S, Heggeness M . Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002; 162(19):2217-22. DOI: 10.1001/archinte.162.19.2217. View

18.

Sheehan J, Mohamed F, Reilly M, Perry I . Secondary prevention following fractured neck of femur: a survey of orthopaedic surgeons practice. Ir Med J. 2000; 93(4):105-7. View

19.

Majumdar S, Beaupre L, Harley C, Hanley D, Lier D, Juby A . Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med. 2007; 167(19):2110-5. DOI: 10.1001/archinte.167.19.2110. View

20.

Kamel H, Bida A, Montagnini M . Secondary prevention of hip fractures in veterans: can we do better?. J Am Geriatr Soc. 2004; 52(4):647-8. DOI: 10.1111/j.1532-5415.2004.52178_6.x. View